{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anthracycline&page=2",
    "query": {
      "intervention": "anthracycline",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=anthracycline&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T12:58:06.058Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03020030",
      "title": "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia, Pediatric"
      ],
      "interventions": [
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Erwinia asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "CYTARABINE",
          "type": "DRUG"
        },
        {
          "name": "DASATINIB",
          "type": "DRUG"
        },
        {
          "name": "DEXAMETHASONE",
          "type": "DRUG"
        },
        {
          "name": "Dexrazoxane",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "ETOPOSIDE",
          "type": "DRUG"
        },
        {
          "name": "HYDROCORTISONE",
          "type": "DRUG"
        },
        {
          "name": "LEUCOVORIN CALCIUM",
          "type": "DRUG"
        },
        {
          "name": "MERCAPTOPURINE",
          "type": "DRUG"
        },
        {
          "name": "METHOTREXATE",
          "type": "DRUG"
        },
        {
          "name": "NELARABINE",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 560,
      "start_date": "2017-03-03",
      "completion_date": "2034-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03020030"
    },
    {
      "nct_id": "NCT00165139",
      "title": "Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Ewings Sarcoma",
        "Non-rhabdomyosarcoma Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Adriamycin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide (VP-16)",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "G-CSF (granulocyte-colony stimulating factor)",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "Up to 19 Years"
      },
      "enrollment_count": 20,
      "start_date": "1996-01",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2009-11-02",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00165139"
    },
    {
      "nct_id": "NCT00656617",
      "title": "Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "15 Years to 65 Years"
      },
      "enrollment_count": 106,
      "start_date": "2008-04",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2015-03-09",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00656617"
    },
    {
      "nct_id": "NCT00080197",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Metastases"
      ],
      "interventions": [
        {
          "name": "E7070",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 250,
      "start_date": "2004-02",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2006-10-11",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Sedona, Arizona + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Torrington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00080197"
    },
    {
      "nct_id": "NCT05283720",
      "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Epcoritamab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride [HCl]",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Polatuzumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "CC-99282",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2022-06-14",
      "completion_date": "2032-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 18,
      "location_summary": "Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283720"
    },
    {
      "nct_id": "NCT07823491",
      "title": "Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Resectable Liposarcoma",
        "Resectable Soft Tissue Sarcoma",
        "Resectable Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Transthoracic Echocardiography Test",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 228,
      "start_date": "2026-12-01",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07823491"
    },
    {
      "nct_id": "NCT00003776",
      "title": "Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "trimetrexate glucuronate",
          "type": "DRUG"
        },
        {
          "name": "surgical procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-12",
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-21",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003776"
    },
    {
      "nct_id": "NCT05578976",
      "title": "A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Epcoritamab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 900,
      "start_date": "2023-02-08",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 68,
      "location_summary": "Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05578976"
    },
    {
      "nct_id": "NCT03587662",
      "title": "Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Kidney Medullary Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "SMARCB1 Negative",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib Citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-08-17",
      "completion_date": "2026-08-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03587662"
    },
    {
      "nct_id": "NCT06047080",
      "title": "An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Polatuzumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1130,
      "start_date": "2023-09-18",
      "completion_date": "2030-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-24T12:58:06.058Z",
      "location_count": 60,
      "location_summary": "Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06047080"
    }
  ]
}